Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SynektikFRA:A2P -0.12%67 5-Year Yield-on-Cost % is 68.02 as of Jul. 25, 2026, which is 77% above its 10-year median of 38.42. GuruFocus rates FRA:A2P with a GF Score™ of 67/100 and a GF Value™ of €53.63 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 324 Medical Devices & Instruments companies, Synektik ranks better than 98.77% on this metric.
Synektik's yield on cost for the quarter that ended in Mar. 2026 was 68.02.
The historical rank and industry rank for Synektik's 5-Year Yield-on-Cost % or its related term are showing as below:
FRA:A2P'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 9.94 Med: 38.42 Max: 104.01
Current: 68.02
During the past 13 years, Synektik's highest Yield on Cost was 104.01. The lowest was 9.94. And the median was 38.42.
FRA:A2P's 5-Year Yield-on-Cost % is ranked better than 98.77% of 324
companies
in the Medical Devices & Instruments industry
Industry Median: 2.515
vs FRA:A2P: 68.02
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Synektik 5-Year Yield-on-Cost % Related Terms
FRA:A2P vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, Synektik's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synektik 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Synektik's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Synektik's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Synektik is calculated as
Synektik (FRA:A2P) has a 5-Year Yield-on-Cost % of 68.02 as of Jul. 25, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Synektik and its competitors. This is 77% above median its historical median of 38.42. Over the past decade, Synektik's 5-Year Yield-on-Cost % has ranged from 9.94 to 104.01. According to the industry distribution chart, Synektik ranks #4 out of 324 companies in the Medical Devices & Instruments industry, placing it in the top 1.2%.
Is Synektik's 5-Year Yield-on-Cost % too high?
Synektik's current 5-Year Yield-on-Cost % of 68.02 is 77% above median its 10-year median of 38.42. Over the past 10 years, this metric has ranged from a low of 9.94 to a high of 104.01. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.52. Synektik's value of 68.02 is 2604.6% above this industry median. Based on the distribution chart, Synektik ranks #4 out of 324 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Synektik has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Synektik's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Synektik ranks #4 out of 324 companies for 5-Year Yield-on-Cost %. This places Synektik in the top 1% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.52. Synektik's value of 68.02 is 2604.6% above this benchmark. Historically, Synektik's own 5-Year Yield-on-Cost % has ranged from 9.94 to 104.01 over the past decade. While the company's 10-year median is 38.42 vs. the industry median of 2.52, Synektik has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.52, based on 324 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Synektik's current 5-Year Yield-on-Cost % of 68.02 is 2604.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Synektik and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synektik's current 5-Year Yield-on-Cost % is 68.02, which is 77% above median its own 10-year median of 38.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synektik stock overvalued right now?
Based on GuruFocus' analysis, Synektik (FRA:A2P) is currently considered Significantly Overvalued. The stock's GF Value™ is €53.63, compared to a current price of €82.80 — trading 54.4% above its estimated fair value. The current 5-Year Yield-on-Cost % is 68.02, which is 77% above median its 10-year median of 38.42 and 2604.6% above the Medical Devices & Instruments industry median of 2.52. Synektik's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Synektik (FRA:A2P), the current 5-Year Yield-on-Cost % is 68.02 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synektik (FRA:A2P) Overvalued in 2026?
Based on GuruFocus' analysis, Synektik stock appears to be overvalued.
The current stock price of €82.80 is trading 54.4% above its estimated GF Value™ of €53.63.
GuruFocus considers Synektik to be Significantly Overvalued.
Key valuation signals for FRA:A2P:
5-Year Yield-on-Cost %: 68.02 (77% above median its 10-year median of 38.42)
GF Value™: €53.63 vs. price of €82.80 (54.4% above fair value)
Industry Position: 2604.6% above the Medical Devices & Instruments median (#4 of 324)
No single metric tells the full story. See the FRA:A2P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synektik SA is a supplier of innovative products, services and IT solutions for diagnostic imaging and nuclear medicine. It sells medical devices and IT solutions used in radiology and operates research laboratory for diagnostic imaging systems and a service centre for medical equipment. Its operating segments include the sale of medical equipment used in radiology and nuclear medicine and IT solutions, Maintenance services for medical equipment as well as acceptance and specialist tests and Radiopharmaceutical production.
67GF Score
Get the complete analysis for FRA:A2P
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:A2P has been successfully added to your 
